ClinicalTrials.gg
RecruitingNCT06749847MIRABELLEUpdated Jul 23, 2025

HPV Self-sampling in the General Population

An interventional study of Women receive invitation letter with HPV self-sampling kit and Women receive invitation letter with choice of ordering a free self-sampling kit or visit healthcare provider in Cervical Cancer, sponsored by International Agency for Research on Cancer. Recruiting at 2 sites in France. Open to female participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-23.

Sponsored by International Agency for Research on Cancer · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
6,000
Allocation
Randomized
Ages
30 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 147 studies in Uterine Cervical Neoplasms with a site in France — 31 open to participants now, 46 under way, 5 of them phase 3. Uterine Cervical Neoplasms · France.

Planned enrollment
7th of 117
6,000 · median 210
Started
2025
with 8 others
No phase
45 of 147
9 open now
Primary completion
2026-06
later than 7 of 45 live
Registered
136th of 147
by date

Among the 147 studies in Uterine Cervical Neoplasms with a site in France, this one is the 7th largest by planned enrollment of the 117 interventional ones that give a count, is one of 9 that started in 2025, is one of 45 with no phase, reaches primary completion later than 7 of the 45 other live ones, and was the 136th registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

31 of the 147 studies in Uterine Cervical Neoplasms with a site in France are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 30 Years to 65 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies in Uterine Cervical Neoplasms with a site in France, or all of them as a file.
02

Study summary

A randomized controlled trial comparing three strategies for cervical cancer screening: direct mailing of HPV self-sampling kit ("Outreach" arm), choice between self-sampling or healthcare provider sampling ("Choice" arm), and standard care (control arm) in two French departments.

Read the detailed description

In France, over 3,000 women are diagnosed annually with cervical cancer and 1,100 die from it, despite organized screening programs. The national screening coverage rate of 59% (2018- 2020) remains well below the European Union's recommended target of 70% and even further from the French Cancer Plan 2014-2019 objective of 80%. This study evaluates two innovative strategies to improve participation rates in two French departments (Marne and Aube). Eligible women aged 30-65 years will be randomized into three arms. The "Outreach" arm receives HPV self-sampling kit directly at home with SMS reminder at 3 months if no participation. The "Choice" arm can choose between ordering a self-sampling kit or visiting a healthcare provider with SMS reminder at 3 months if no participation. The control arm follows standard procedure with self-sampling offered at 12-month reminder. Women with positive HPV self-sampling tests will be followed for triage cytology, with assistance provided for appointments in the "Outreach" arm and reminders at 6 months post-positive result in the "Choice" arm. The study assesses participation rates, triage completion rates, feasibility, acceptability, and cost-effectiveness of these strategies. If successful, findings could inform modifications to the national organized screening program.

03

Conditions studied

  • Cervical Cancer

Keywords

  • Cervical cancer
  • screening program
  • pilot project
  • randomised control trial
  • France
04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged 30 to 65 years old
  • Living in the study area (Departments of Marne and Aube, France)
  • At moderate risk of cervical cancer, i.e. eligible to the organised programme and receiving the first invitation of the screening round (not a reminder letter)

Exclusion criteria

Exclusion Criteria:

  • Outside the target age (less than 30 years old, or 66 years old and more)
  • Already participating in the current screening round
  • Total hysterectomy
  • History of cervical cancer
  • Current follow-up for abnormal cervical screening result or cervical lesions
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
6,000 participants (estimated)

Study arms

  • Experimental
    Outreach

    Women receive invitation letter with HPV self-sampling kit; Direct mailing of HPV self-sampling kit; Women receive HPV self-sampling kit with instructions; SMS reminder at 3 months if no participation; Assistance provided for triage cytology if HPV positive.

    Other: Women receive invitation letter with HPV self-sampling kit

  • Experimental
    Choice

    Women receive an invitation letter offering a choice between ordering a free self-sampling kit or visiting a healthcare provider. Option between self-sampling and healthcare provider: women can choose testing method. If self-sampling chosen, kit sent to home. SMS reminder at 3 months if no participation.

    Other: Women receive invitation letter with choice of ordering a free self-sampling kit or visit healthcare provider

  • No intervention
    Control arm

    Standard invitation to visit healthcare provider for cervical cancer screening. Standard screening procedure. Follow standard organized screening program procedure. HPV self-sampling offered at 12-month reminder if no participation.

Interventions

  • OtherWomen receive invitation letter with HPV self-sampling kit

    Direct mailing of HPV self-sampling kit. Women receive HPV self-sampling kit with instructions. SMS reminder at 3 months if no participation. Assistance provided for triage cytology if HPV positive.

  • OtherWomen receive invitation letter with choice of ordering a free self-sampling kit or visit healthcare provider

    Option between self-sampling and healthcare provider: women can choose testing method. If self-sampling chosen, kit sent to home. SMS reminder at 3 months if no participation.

06

What researchers measure

Primary outcomes

  1. Participation rate in cervical cancer screening

    Time frame: 18 months after invitation

Secondary outcomes

  1. Triage cytology completion rate after positive HPV test

    Time frame: 6 months after positive result

  2. HPV positivity rate

    Time frame: 12 months after invitation

  3. Invalid result rate

    Time frame: 18 months

  4. Time from HPV-positive result to completion of cytological triage

    Time frame: 18 months

  5. Women's acceptability of HPV self-sampling

    Qualitative assessment through semi-structured interviews with 40 women to assess women's acceptability of HPV self-sampling

    Time frame: 24 months

  6. Cost-effectiveness of screening strategies

    Costs will be estimated using an ingredients approach whereby resources used for the respective interventions (' Outreach ' and ' Choice' strategies) are identified and valued. The analysis will include all costs incurred by the screening program, including invitation materials, self-sampling kits, laboratory testing, result communication, and follow-up coordination. The incremental cost-effectiveness ratios (ICERs) will be calculated as the mean difference in total costs between each intervention arm and the control arm, divided by the mean difference in screening participation rates. Results will be expressed in euros per percentage change in screening participation.

    Time frame: 24 months

07

Study locations

2 of 2 sites recruiting
  • Regional Cancer Screening Coordinating Centre, Aube site
    Troyes, Aube 10000, France
    Recruiting
  • Regional Cancer Screening Coordinating Centre, Marne site
    Reims, Marne 51100, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2026, 12 months after the start.

Of 446 non-industry interventional studies with no phase under Uterine Cervical Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 71. This study's planned 12 months is below that.

Counting every sponsor, half of 462 studies reached it within 33 months; a quarter within 15 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2024
First posted
Dec 27, 2024
StartActual
Jun 26, 2025
Primary completionEst.
Jun 30, 2026
CompletionEst.
Dec 31, 2026
Last update
Jul 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06749847
Lead sponsor
International Agency for Research on Cancer
Collaborators
National Cancer Institute, France, Central Hospital, Nancy, France, CHU de Reims
Responsible party
Sponsor
First posted
Dec 27, 2024
Start date
Jun 26, 2025
Primary completion
Jun 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 23, 2025

Study contacts

Farida Selmouni, PhD
Contact
selmounif@iarc.who.int
+33 4 72738485
Catherine Sauvaget, MD, PhD
Contact
sauvagetc@iarc.who.int
+33 4 72738485
Aurélie BERTRAND-BRICE, MD
principal investigator · Regional Cancer Screening Coordinating Centre, Marne site
Christine CLAVEL CRAVOISIER, Professor
principal investigator · CHU de Reims
Hamza ACHIT, PhD
principal investigator · CHRU Nancy
Farida SELMOUNI, PhD
principal investigator · International Agency for Research on Cancer
Catherine SAUVAGET, MD, PhD
principal investigator · International Agency for Research on Cancer

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion